Ferrante M, Panaccione R, Baert F, Bossuyt P, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's
disease: results from the multicentre, randomised, double-blind,
placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 2022;399:2031-2046.
PMID: 35644155